+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Atherosclerosis Therapeutics Market 2019-2023 - Product Image

Global Atherosclerosis Therapeutics Market 2019-2023

  • ID: 4825180
  • Report
  • Region: Global
  • 136 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi.
  • MORE
Global Atherosclerosis Therapeutics Market: About this market

Atherosclerosis occurs due to the development of plaque inside the artery, which later hardens and becomes thick. This hardened plaque narrows the artery which decreases the blood supply to body parts. The atherosclerosis therapeutics market analysis considers sales from small molecules and biologics. Our analysis also considers the sales of atherosclerosis therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant share, and this trend is expected to continue over the forecast period. Factors such as the availability of a wide range of drugs for the treatment of atherosclerosis will play a significant role in the small molecule segment to maintain its market position. Also, our global atherosclerosis therapeutics market report also looks at factors such as increased risk factors of atherosclerosis, availability of advanced diagnostic methods and rising prevalence of hypercholesterolemia. However, uncertainties in the side-effects associated with atherosclerosis therapeutics, product recalls, and stringent regulatory environment may hamper the growth of the atherosclerosis therapeutics market over the forecast period.

Global Atherosclerosis Therapeutics Market: Overview

Demand for the availability of advanced diagnostic methods

The advanced diagnostic techniques employed for diagnosis of atherosclerosis have undergone significant improvements in terms of technology and high-definition picture quality and provide information about the presence, size, and the composition of the plaque. These advanced diagnostic methods will lead to the expansion of the global atherosclerosis therapeutics market at a CAGR of over 5% during the forecast period.

Rising focus on identification of new drug targets for atherosclerosis

The current research on atherosclerosis focuses on evaluating new drug targets that have genetic and mechanistic links. Efforts in this area have revealed some new pro-atherosclerotic pathways and can significantly reduce the risk of atherosclerosis. Growing R&D effects in this area are expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global atherosclerosis therapeutics market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global atherosclerosis therapeutics manufacturers, that include AstraZeneca Plc, Bayer AG, Merck & Co. Inc., Novartis AG, Sanofi.

Also, the atherosclerosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Identification of new pathogenic targets
  • Identification of new drug targets for atherosclerosis
  • Strong incidence of coronary heart disease (CHD)
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bayer AG
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Hypothesis behind LDL deposition in intima
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Some of the key clinical trials in global atherosclerosis therapeutics market
Exhibit 20: Product - Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 24: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Adoption rate of health insurance coverage among US adults with CHD, or a stroke, or both, 2019
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Incidence rate of CHD in adults aged 45 years and above 2019
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AstraZeneca Plc - Vendor overview
Exhibit 53: AstraZeneca Plc - Business segments
Exhibit 54: AstraZeneca Plc - Organizational developments
Exhibit 55: AstraZeneca Plc - Geographic focus
Exhibit 56: AstraZeneca Plc - Key offerings
Exhibit 57: AstraZeneca Plc - Key customers
Exhibit 58: Bayer AG - Vendor overview
Exhibit 59: Bayer AG - Business segments
Exhibit 60: Bayer AG - Organizational developments
Exhibit 61: Bayer AG - Geographic focus
Exhibit 62: Bayer AG - Segment focus
Exhibit 63: Bayer AG - Key offerings
Exhibit 64: Bayer AG - Key customers
Exhibit 65: Merck & Co. Inc. - Vendor overview
Exhibit 66: Merck & Co. Inc. - Business segments
Exhibit 67: Merck & Co. Inc. - Organizational developments
Exhibit 68: Merck & Co. Inc. - Geographic focus
Exhibit 69: Merck & Co. Inc. - Segment focus
Exhibit 70: Merck & Co. Inc. - Key offerings
Exhibit 71: Merck & Co. Inc. - Key customers
Exhibit 72: Novartis AG - Vendor overview
Exhibit 73: Novartis AG - Business segments
Exhibit 74: Novartis AG - Organizational developments
Exhibit 75: Novartis AG - Geographic focus
Exhibit 76: Novartis AG - Segment focus
Exhibit 77: Novartis AG - Key offerings
Exhibit 78: Novartis AG - Key customers
Exhibit 79: Sanofi - Vendor overview
Exhibit 80: Sanofi - Business segments
Exhibit 81: Sanofi - Organizational developments
Exhibit 82: Sanofi - Geographic focus
Exhibit 83: Sanofi - Segment focus
Exhibit 84: Sanofi - Key offerings
Exhibit 85: Sanofi - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors
    Note: Product cover images may vary from those shown
    3 of 4

    Loading
    LOADING...

    4 of 4

    FEATURED COMPANIES

    • AstraZeneca Plc
    • Bayer AG
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi.
    • MORE
    The following companies are recognised as the key players in the global atherosclerosis therapeutics market: AstraZeneca Plc, Bayer AG, Merck & Co. Inc., Novartis AG, Sanofi.

    Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising focus on identification of new drug targets for atherosclerosis.”

    According to the report, one of the major drivers for this market is demand in the availability of advanced diagnostic methods.

    Further, the report states that one of the major factors hindering the growth of this market is the side-effects associated with atherosclerosis therapeutics.

    The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
    Note: Product cover images may vary from those shown
    5 of 4
    • AstraZeneca Plc
    • Bayer AG
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi.
    Note: Product cover images may vary from those shown
    Adroll
    adroll